Cargando...
Transient Nutlin-3a treatment promotes endoreduplication and the generation of therapy-resistant tetraploid cells
P53 activity is controlled in large part by MDM2, an E3 ubiquitin ligase that binds p53 and promotes its degradation. The MDM2 antagonist Nutlin-3a stabilizes p53 by blocking its interaction with MDM2. Several studies have supported the potential use of Nutlin-3a in cancer therapy. Two different p53...
Guardado en:
| Autores principales: | , , |
|---|---|
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
2008
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2674275/ https://ncbi.nlm.nih.gov/pubmed/18922897 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-08-1901 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|